Skip to Main Content

Paper Details

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Oncotarget
76
2016
MDS, TP53, TP53 mutation, TP53 mutations, TP53-mutated MDS, myelodysplastic syndromes, patients
Author NameAffiliation
Jianhua ZhangThe University of Texas MD Anderson Cancer Center
Jianhua ZhangThe University of Texas MD Anderson Cancer Center
Curtis GumbsThe University of Texas MD Anderson Cancer Center
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
Jorge CortesThe University of Texas MD Anderson Cancer Center
Phillip A FutrealThe University of Texas MD Anderson Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
  • 1 - 8

Datasets

Release 1.2